Phase 2 N=22 Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract
Metastatic Transitional Cell Cancer of the Urothelial Tract
Primary: Response Rate — 11 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=37 Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy
Spinal and Bulbar Muscular Atrophy
Primary: Number of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths as a Measure of Safety and Tolerability — 2; 4; 2; 1 Participants
Phase 2 N=102 NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia
Tardive Dyskinesia
Primary: Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Change From Baseline at Week 6 — -0.3; -3.4 units on a scale — p=<.0001
Phase 2 N=275 Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
Fallopian Tube Cancer · Metastatic Cancer · Ovarian Cancer
Primary: 9-month Progression Rate Post-randomization — 0.386; 0.347; 0.245 Porportion of participants — p=0.065
Phase 2 N=9 Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant
Single Umbilical Cord Blood Transplantation · Non-myeloablative Conditioning · Acute Lymphocytic Leukemia
Primary: Absence of Graft Failure at Day 42 — 0 Participants
Phase 2 N=53 Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Adult Cholangiocarcinoma · Advanced Adult Hepatocellular Carcinoma · BCLC Stage C Adult Hepatocellular Carcinoma
Primary: Overall Survival — 4.3; 7.9 months — p=0.05
Phase 2 N=37 NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Tardive Dyskinesia
Primary: Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score — 9.9; 9.1; 8.8 units on a scale — p=0.5880
Phase 2 N=68 Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas
Non-Hodgkin's Lymphoma
Primary: Percentage of Patients With Complete Response to the Combination Chemotherapy — 75.0; 23.0 Percentage of participants
Phase 2 N=45 De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca
Carcinoma, Squamous Cell · Head and Neck Neoplasms · Oropharyngeal Neoplasms
Primary: Pathologic Complete Response Rate After De-escalated CRT in HPV-positive and/or p16 Positive Oropharyngeal Squamous Cell Carcinoma (OPSCC). — 37 Participants
Phase 2 N=138 The Efficacy and Safety of Clonidine Hydrochloride Topical Gel, vs Clonidine Hydrochloride Gel Comparator to Treat Painful Diabetic Neuropathy
Painful Diabetic Neuropathy · Diabetic Neuropathy · Neuropathy
Primary: Change From Baseline to Day 84 (Week 12) in Numeric Pain Rating Scale Score — -1.2; -1.4 units on a scale — p=0.3361
Phase 2 N=14 Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
Urothelial Carcinoma
Primary: Overall Response Rate — 11 Participants
Phase 2 N=106 Glutamine for the Treatment of Patients With Irritable Bowel Syndrome
Diarrhea-Predominant Irritable Bowel Syndrome
Primary: Change in the Irritable Bowel Symptom Severity Scale — 181; 301 units on a scale
Phase 2 N=40 Measuring the Amount of Methadone or Morphine in the Blood of Neonates, Infants & Children After Cardiac Surgery.
Pain
Primary: Maximum Concentration of Morphine Including Its Metabolites (Morphine-3-glucuronide and Morphine-6-glucuronide) — 27.55; 225; 22.95 ng/mL
Phase 2 N=116 A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma
Multiple Myeloma
Primary: Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 0; 1; 2 participants
Phase 2 N=45 Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia
Relapsed/Refractory Philadelphia Positive B-precursor ALL
Primary: Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery (CR/CRh*) During the First Two Treatment Cycles — 35.6…